vaccines to prevent and treat cancer

Upload: the-royal-society-of-edinburgh

Post on 02-Apr-2018

214 views

Category:

Documents


0 download

TRANSCRIPT

  • 7/27/2019 Vaccines to Prevent and Treat Cancer

    1/3

    The Royal Society of EdinburghJoint lecture with the Scottish Cancer Foundation,

    supported by the Cruden Foundation

    Vaccines to Prevent and Treat Cancer

    Professor Ian Frazer FRSCEO and Director of Research,

    Translational Research Institute, Brisbane, Australia

    24 J une 2013

    Report by J ennifer Trueland

    Sometimes described as Gods gift to women for his work in developing the HPVvaccine which aims to wipe out cervical cancer, Professor Ian Frazer gave some

    fascinating insights into the role that immunotherapy already plays in preventing andtreating cancers as well as some glimpses to the future.

    If hed been asked to give this talk 20 or 30 years ago, said Professor Frazer, itwould have been a very short lecture indeed; its only recently that weve known forsure that viruses cause cancer in humans. Likewise, using the immune system toprevent or treat cancer is a relatively new concept, but one in which there has beentremendous progress in the last two to three decades.

    In his lecture, Glasgow-born and Edinburgh-educated Professor Frazer outlined the21st Century challenge of healthy ageing, explained why cancer is such an importanttarget, and looked at what can be done to prevent and treat it. He focused inparticular on the human papilloma virus (HPV), which causes cervical cancer, and onthe vaccine (which he was instrumental in developing) that is already drasticallyreducing incidence of the disease in countries running immunisation programmes.Finally, he looked at the prospects for using immunotherapy to treat established HPVinfection, and the challenges that remain.

    So why should we focus on cancer? In Australia, cancer is the most common causeof death, and there have been estimates that this will be the case worldwide by 2050.Around 70 per cent of cancer is preventable (with effort) and we can now curearound 50 per cent. Our chances of getting cancer depend on our genes (accountingfor around 10 per cent of risk); what we do to ourselves, for example, smoking (30

    per cent); what we do to the environment (30 per cent); and what we catch it from (30per cent).

    Theres quite a list of things we can do to prevent cancer, he said, but themessages have tended to be confusing, and too full of thou shalt nots. For example,on one page of a newspaper it might say that coffee prevents cancer, while anotherpage might say it causes it. Its not just about telling people what they need to do,he added, although he pointed out that behaviour modification is effective. Forexample, smoking accounts for around 40 per cent of avoidable cancer worldwide,obesity (in the developed world) around 10 per cent, and alcohol also around 10 percent. If these avoidable cancers were prevented, then it would save around 30 percent of healthcare costs and mean more money was available for medical

    research, and for treating the cases that remained.

    Immunotherapy, that is, using the immune system to tackle disease, is now anestablished component of cancer therapy. There are several approaches. These

  • 7/27/2019 Vaccines to Prevent and Treat Cancer

    2/3

    include prophylactic vaccines, for example, hepatitis B and HPV, and usingimmunotherapy to treat cancers in practice, for example, Herceptin for breast cancer.Around 20 per cent of cancers are caused by infections, including papillomavirus,hepatitis B and C, and Epstein Barr virus. Focusing in particular on cervical cancer,he pointed out that it is a disease of the developing world.

    Over the years, there have been a number of theories about what causes cervicalcancer; perhaps most notably (following a study comparing incidence among nuns tothat among non-nuns, which found abnormal cells in the latter but not the former)that it is not caused by licentious behaviour but that the risk is greater amongwomen who are excessively sensitive morally. It is now established, however, thatcervical cancer is a rare consequence of chronic infection with papilloma viruses,which are transmitted sexually. Since it is a challenge to control infection, it is betterto prevent it hence the search for a vaccine.

    [At this point Professor Frazer declared a potential conflict of interest, in that he andthe University of Queensland benefit financially from the commercial sale of theprophylactic HPV vaccines discussed in the talk.]

    It was around 1980 that Harald zur Hausen found the viral link between HPV andcancer; he was disbelieved at first, but went on to win a Nobel Prize. HPV infection iscommon, and 95 per cent will resolve spontaneously, but around two per cent willprogress to cancer over 15 years. Unusually, it is possible to detect pre-cancerouscells one to two years after infection it is these cells which are detected viascreening programmes, when treatment will be effective in most cases.

    It took around 15 years to develop an HPV vaccine, in what Professor Frazerdescribed as a billion-dollar process. Development of the vaccine was possiblebecause of genetic engineering research, and was challenging in as much as itnecessarily had to involve many thousands of people and a hard end point to prove

    efficacy, and even more to prove safety. Post-marketing surveillance has shown thatfrom 44,000,000 doses over 24 months, 12,424 people reported possibly associatedevents, mostly non-serious, with fainting the most common. Adverse events inpregnancy were similar in both the vaccine and the placebo groups.

    Following the introduction and good uptake of the vaccine in Australia, theproportion of Australian-born women with genital warts fell markedly (in younger agegroups). The proportion of heterosexual men diagnosed with genital warts also fell(across all age groups) suggesting that vaccinating women protects men (who werenot vaccinated) too.

    Professor Frazer described a project to introduce an immunisation programme inVanuatu, a group of islands off Australia with just five doctors for 250,000 people,one vaccine fridge, no reliable electricity, and high risk of HPV infection andassociated pre-cancer. Immunisation was delivered as part of a programme whichincluded educational sessions, aimed at parents, children, school staff andgovernment. The people of Vanuatu were keen to protect their women, and uptakerates were high. Mothers tell their children: get this shot, he said.

    Bhutan, a poor country which values its health, did it too, largely down to influencefrom the royal grandmother, he added. Professor Frazer said the case forintroducing immunisation programmes worldwide is compelling, adding that theevidence suggested it has a bigger impact in terms of benefit than the polio vaccine.

    But what about when the virus is already there? Professor Frazer said there is noevidence that cervical cancer vaccines are therapeutic for existing HPV vaccines.Despite promising results in the lab, it has to be borne in mind that mice lie, he

  • 7/27/2019 Vaccines to Prevent and Treat Cancer

    3/3

    added. Immunotherapy [for existing HPV infection] might work in animals, but not inhumans. Although, apparently, theres a good immune response to the vaccine,vaccination makes no change to colposcopy and histology.

    Researchers continue to work on several likely leads. For example, it would appearthat adding inflammation to the mix could help mobilise the immune system to beatthe virus. An early (Phase 1b) trial on patients with recurrent genital warts has shownthat while the vaccine alone is ineffective, immunotherapy and inflammation worksbetter than either alone. This is a basis for clinical trials, he added. A similarapproach may also prove successful in treating squamous skin cancers, which are amajor problem for Australia.

    The take-home message, he concluded, is that vaccines to prevent HPV-associated cancer should rapidly reduce disease burden where they are deployed,that immunotherapy for HPV infections may be possible, but epithelial immunology isfocused on minimising damage and there are some technical barriers to overcome,and that embedding research in health practice is critical to moving forward withhealth care.

    Questions

    Asked about the issue of whether boys should be vaccinated against HPV, ProfessorFrazer said hed taken the decision to vaccinate his male children back in 2006. TheAustralian government has taken a similar decision this year. Although vaccinatinggirls does give a measure of protection to boys, this doesnt protect them overseas,for example. Boys deserve protection and there is a reasonable case for vaccination,he said.

    Asked whether there is evidence that the ability to clear the virus is associated withdeprivation, Professor Frazer said that around two per cent of the population getpersistent infection, but there is no evidence that environmental factors are at play it could just be random chance, he said.

    Responding to a question about the potential of vaccines for other cancers,Professor Frazer said that even the vaccines we have arent always used, and thatwe should be grateful for those, and make sure they are deployed. He said it costspharmaceutical companies a huge amount to develop vaccines, and that some havebeen burned by vaccines which havent worked after years of investment.

    Asked to compare the value of screening and vaccination, Professor Frazer said bothare important. Screening is relatively low tech, but with vaccination, youre acting

    now to see the benefits in 20 years time.

    Getting the message out there is important, particularly in areas such as sub-Saharan Africa, where groups such as the First Ladies Club which promote publichealth initiatives are influential. Build on the infrastructure that works, he said.

    Vote of ThanksProfessor Bob Steele of the University of Dundee thanked Professor Frazer for hismasterly lecture and enormous contribution to human health worldwide.

    Opinions expressed here do not necessarily represent the views of the RSE, nor of its FellowsThe Royal Society of Edinburgh, Scotlands National Academy, is Scottish Charity No. SC000470